Last reviewed · How we verify

NCT04685343

Behavioral and Neural Phenotypes of Primary Dysmenorrhea in Adolescents

Completed NA Last updated 22 January 2026
What this trial tests

NA trial testing Quantitative Sensory Testing in Primary Dysmenorrhea in 164 participants. Completed in 24 December 2025.

Timeline
14 December 2020
Primary endpoint
24 December 2025
24 December 2025

Quick facts

Lead sponsorMclean Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment164
Start date14 December 2020
Primary completion24 December 2025
Estimated completion24 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mclean Hospital

Who can join

Adults 13 to 19, female only, with Primary Dysmenorrhea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will use primary dysmenorrhea (PD; menstrual pain without an identified organic cause) as a model to examine biomarkers associated with menstrual and non-menstrual bodily pain in adolescent girls, ages 13-19. Participants will undergo extensive phenotyping including pain inhibition testing and multimodal neuroimaging to obtain indices brain structure and function at baseline and 12 months later. Menstrual pain severity and non-menstrual bodily pain will be assessed monthly for 24 months. Aims of the study are: 1) to identify the central mechanisms of PD using measures of pain inhibition and brain structure and connectivity of sensorimotor, default, emotional arousal, and salience networks, 2) to determine deficits in pain inhibition and alterations in brain structure and network connectivity that predict the one-year developmental trajectories of menstrual pain and non-menstrual bodily pain, and 3) to identify the dynamic relationship between alterations in pain inhibition and brain structure and connectivity with symptom change in menstrual pain and non-menstrual bodily pain. We hypothesize that deficits in endogenous pain inhibition and alterations in brain structure, connectivity, and function of regional networks will be positively associated with menstrual pain severity ratings at baseline and predict the trajectory of menstrual and non-menstrual bodily pain over 2 years. The results are expected to identify specific mechanisms and characteristics that predict the transition from acute/cyclical pain to persistent or chronic pain, which will support the development of therapies to prevent the transition from recurrent to chronic pain in adulthood.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Validation of the menstrual sensitivity index in adolescents.
    Seidman LC, Handy AB, Payne LA. · · 2025 · PMID 40787629 · DOI 10.1097/pr9.0000000000001315

Verify or expand the search:

Other trials of Quantitative Sensory Testing

Trials testing the same drug.

Other recruiting trials for Primary Dysmenorrhea

Currently open trials in the same condition.

Other Mclean Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04685343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing